04
2019
-
07
Wuhan Zhongbo changed its name to "Sinopharm Animal Insurance"
(Source: "China Animal Husbandry Network" on January 17, 2019)
Recently, with the approval of the State Administration for Industry and Commerce, "Wuhan Zhongbo Biological Co., Ltd." was renamed "Sinopharm Group Animal Health Co., Ltd.", and "Sinopharm Animal Health" was launched.
The animal health sector is an important part of the "jigsaw puzzle" of China Biotechnology Corporation's development strategy, and it is also an important measure to implement the strategic concept of China National Pharmaceutical Group's biomedical health industry cluster. On December 5, 2016, Wuhan Zhongbo completed the legal procedures for capital increase and share expansion and became an animal health enterprise under China Biotechnology. In December 2017, Wuhan Zhongbo wholly owned Sinopharm Group Yangzhou Weike Bioengineering Co., Ltd., laying the framework foundation for Sinopharm's animal health sector.
In 2018, Wuhan Zhongbo actively explored the possibility of obtaining potential varieties or high-quality enterprises in the industry by means of cooperation, mergers and acquisitions, holding or equity participation, etc., committed to capital operation, strived to achieve extensional and leapfrog development, consolidated Sinopharm's muscles and bones, and achieved initial results.
The approval of "Sinopharm Animal Health Care" is a new milestone in the great development of China National Pharmaceutical Group's animal health care industry. How to build Sinopharm's animal health sector and what its development prospects are, from China National Pharmaceutical Group to the senior management of China Biotechnology, all attach great importance to it, and domestic counterparts are also highly concerned.
RELATED INFORMATION